Overview

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Status:
Withdrawn

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This study evaluates the safety of PVSRIPO treatment in combination with Atezolizumab in patients with WHO grade IV malignant glioma. All patients will receive a single PVSRIPO infusion followed by atezolizumab infusions every three weeks for up to two years.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Darell Bigner
Darell D. Bigner, MD, PhD

Collaborators:

Genentech, Inc.
Istari Oncology, Inc.

Treatments:

Antibodies, Monoclonal
Atezolizumab